Related Experiment Video
Updated: Jul 31, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features
Julianna Martel1, Hannah L Hanania2, Anisha B Patel1
1Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA.
Abstract:
Immune checkpoint inhibitors (ICIs) represent an emerging treatment option for a variety of cancer types. Through inhibition of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and/or cytotoxic lymphocyte-associated antigen-4 (CTLA-4), ICIs activate the host's immune system causing a heightened anti-tumor response. However, off-target effects of ICIs can result in numerous different immune-related cutaneous adverse events (irCAEs). Beyond impacting quality of life, irCAEs can lead to dose limitations or discontinuation of anti-cancer therapies. Correct diagnosis is necessary for expedient and appropriate management. Skin biopsies are often performed to increase diagnostic accuracy and guide clinical management. An extensive literature review was performed using the PubMed database to identify the reported clinical and histopathologic features of irCAEs. This comprehensive review primarily details the histopathologic features of various irCAEs reported to date. Clinical presentation and immunopathogenesis are also discussed in relation to histopathology.
Insights
Immune checkpoint inhibitors (ICIs) can cause skin issues called immune-related cutaneous adverse events (irCAEs). Understanding their histopathology is key for accurate diagnosis and managing cancer treatment.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) target PD-1, PD-L1, and CTLA-4 to enhance anti-tumor immunity.
- ICIs are effective cancer treatments but can cause immune-related cutaneous adverse events (irCAEs).
- irCAEs can negatively impact patient quality of life and cancer treatment adherence.
Purpose of the Study:
- To review and detail the histopathologic features of various irCAEs.
- To correlate clinical presentation and immunopathogenesis with histopathology of irCAEs.
- To provide a resource for accurate diagnosis and management of irCAEs.
Main Methods:
- Extensive literature review of PubMed database.
- Identification and analysis of reported clinical and histopathologic features of irCAEs.
- Synthesis of information on irCAE presentation, immunopathogenesis, and histopathology.
Main Results:
- Detailed description of histopathologic findings across a spectrum of irCAEs.
- Discussion of clinical presentations associated with specific histopathologic patterns.
- Exploration of the immunopathogenesis underlying irCAE development.
Conclusions:
- Histopathologic examination of skin biopsies is crucial for diagnosing irCAEs.
- Understanding irCAE histopathology aids in guiding clinical management and treatment decisions.
- This review consolidates key histopathologic information for irCAEs, supporting oncologists and dermatologists.
More Related Videos
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:40Cell-mediated Immune Responses